GENE EDITING OF MONOGENIC DISORDERS IN HUMAN HEMATOPOIETIC STEM CELLS -- CORRECTION OF X-LINKED HYPER-IGM SYNDROME (XHIM)
In certain embodiments methods of treating X-Linked Hyper-IgM Syndrome (XHIM) in a mammal am provided where the methods comprise: i) providing differentiated T cells and/or stem/progenitor cells from the mammal; ii) performing a targeted insertion of a corrective CD40L cDNA at the CD40LG gene locus in said cells to provide a corrected CD40LG gene wherein said targeted insertion places said corrective CD40L cDNA downstream and operably linked to the endogenous CD40LG enhancer/promoter, and iii) introducing said cells into said mammal where said corrected CD40LG gene is expressed in a physiologically regulated manner..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Europäisches Patentamt - (2023) vom: 25. Mai Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
KUO CAROLINE Y [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-05-25, Last update posted on www.tib.eu: 2023-06-30, Last updated: 2023-07-08 |
---|
Patentnummer: |
US2023158110 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA017418569 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA017418569 | ||
003 | DE-627 | ||
005 | 20230708154209.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230630s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA017418569 | ||
035 | |a (EPA)US2023158110 | ||
035 | |a (EPA)68696777 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a KUO CAROLINE Y |e verfasserin |4 aut | |
245 | 1 | 0 | |a GENE EDITING OF MONOGENIC DISORDERS IN HUMAN HEMATOPOIETIC STEM CELLS -- CORRECTION OF X-LINKED HYPER-IGM SYNDROME (XHIM) |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2023-05-25, Last update posted on www.tib.eu: 2023-06-30, Last updated: 2023-07-08 | ||
520 | |a In certain embodiments methods of treating X-Linked Hyper-IgM Syndrome (XHIM) in a mammal am provided where the methods comprise: i) providing differentiated T cells and/or stem/progenitor cells from the mammal; ii) performing a targeted insertion of a corrective CD40L cDNA at the CD40LG gene locus in said cells to provide a corrected CD40LG gene wherein said targeted insertion places said corrective CD40L cDNA downstream and operably linked to the endogenous CD40LG enhancer/promoter, and iii) introducing said cells into said mammal where said corrected CD40LG gene is expressed in a physiologically regulated manner. | ||
650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a bio | |
650 | 4 | |a 615 | |
700 | 0 | |a KOHN DONALD B |4 aut | |
700 | 0 | |a LONG JOSEPH |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 25. Mai |
773 | 1 | 8 | |g year:2023 |g day:25 |g month:05 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/68696777/publication/US2023158110A1?q=US2023158110 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2023 |b 25 |c 05 |
951 | |a AR | ||
952 | |j 2023 |b 25 |c 05 |